Brean Murray Carret & Company

According to a research report published earlier today by Brean Murray Carret, Masimo Corporation (NASDAQ: MASI) is scheduled to report Q4:11 results this evening after close. In the report, Brean Murray Carret commented, “As we had highlighted in our 1/13 update, a careful dig through our model...

According to a research report released today by Brean Murray Carret, Abercrombie & Fitch Co. (NYSE: ANF) is gearing up to meet with a hostile investor group when they announce 4QFY12 on Wednesday morning. “We believe the company will remain resolute in their belief in the longer term growth...

In a recent research report, Brean Murray Carret said it believes that NetApp Inc. (NASDAQ: NTAP) is a $40-$45 stock when taking a 9 month view. Brean Murray Carret commented in the report, “We expect NTAP to guide around Apr Q Street EPS of $1.68B and $0.63 although we expect some conservatism...

According to a research report published today, Brean Murray Carret has downgraded Arch Coal Inc. (NYSE: ACI) from Buy to Hold, as the company is currently in a difficult position to sell its open thermal coal volumes in 2012. Brean Murray Carret commented in the report, “We continue to have a...

According to a research report published today by Brean Murray Carret, Salix Pharmaceuticals (NASDAQ: SLXP) has not been shy about acquiring additional drugs in an effort to diversify itself in the market. In the report, Brean Murray Carret said, “We view IBS-D approval to be a low risk...

Brean Murray Carret reiterates its Buy rating on Activision Blizzard (NASDAQ: ATVI) and raises its price target to $16 from $15 a share following a review of the company's earnings for the fourth quarter and all of 2011. Brean Murray Carret says, "Activision reported strong upside to both 4Q11...

Brean Murray Carret maintains its Hold rating on Ingram Micro (NYSE: IM) as 2H2 catalysts could be incremental to company's recent share appreciation. Brean Murray Carret says, "IM delivered a strong Dec Q, with implied Mar Q EPS in-line with the Street and revenue growth stronger than the Street...

In a recent research report, Brean Murray Carret says that patience is still required on Rentrak Corporation's (NASDAQ: RENT) financials. “We believe Rentrak has moved past the proof of concept stage with a surge in TVEssentials sign-ups among TV broadcasters, and the announcement of a...

In a recent research report, Brean Murray Carret has reiterated its Buy rating and $14 PT on Rick's Cabaret International (NASDAQ: RICK) after the company reported the third consecutive quarter of consistent EPS gains of $0.23. Brean Murray Carret commented in the report, “We believe implementing...

In a research report published today by Brean Murray Carret, ViroPharma Incorporated (NASDAQ: VPHM) received another complete response letter on their Cinryze industrial scale production line. According to the report, “The FDA specified three concerns related to cleaning validation, of which only...

In a recent research report published by Brean Murray Carret, Becton Dickinson (NYSE: BDX) produced a slight revenue beat in FQ1, but maintained clearly low single digit growth. In the report, Brean Murray Carret commented, “Sales of $1.888B (+2.5%, +2.4% FXN) came in slightly ahead of...

Brean Murray Carret & Co. has raised the price target on Rentrak (NASDAQ: RENT) from $21 to $30 and maintains its Buy rating.

Brean Murray Carret & Company has published a research report on Idenix Pharmaceuticals (NASDAQ: IDIX) showing that Gilead Sciences (NASDAQ: GILD) earnings call last night showed a decent profile that may be too good for IDX184 to be viable. Brean Murray reiterates its Sell rating and $3 price...

Brean Murray Carret & Company has raised the price target on Arrow Electronics (NYSE: ARW) from $42 to $48 and maintains its Buy rating.

Brean Murray Carret & Company has raised the price target on Bally Technologies (NYSE: BYI) from $49 to $53 and maintains its Buy rating.